These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27871332)

  • 21. The potential utility of some legal highs in CNS disorders.
    Davidson C; Schifano F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():267-74. PubMed ID: 26232510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist.
    Gibbons S
    Clin Toxicol (Phila); 2012 Jan; 50(1):15-24. PubMed ID: 22248120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EDITORIAL New Psychoactive Substances (NPS), a New Global Issue: Neuropharmacological, Chemical and Toxicological Aspects.
    Pichini S; Busardo FP; Pacifici R; Kintz P
    Curr Neuropharmacol; 2017; 15(5):656-657. PubMed ID: 28000553
    [No Abstract]   [Full Text] [Related]  

  • 24. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
    van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
    J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
    Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
    Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective observational study of emergency department presentations following novel psychoactive substance use.
    Henshall DE; Innes CW; Morrison SR; Wilson B; Brown RA; McAllister SM; Culshaw SL; Reda E
    Scott Med J; 2018 May; 63(2):39-44. PubMed ID: 29514583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intended and unintended use of cathinone mixtures.
    Guirguis A; Corkery JM; Stair JL; Kirton SB; Zloh M; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New psychoactive substances: Purchasing and supply patterns in Australia.
    Sutherland R; Bruno R; Peacock A; Dietze P; Breen C; Burns L; Barratt MJ
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28517235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel psychoactive substances.
    Krabseth HM; Tuv SS; Strand MC; Karinen RA; Wiik E; Vevelstad MS; Westin AA; Øiestad EL; Vindenes V
    Tidsskr Nor Laegeforen; 2016 May; 136(8):714-7. PubMed ID: 27143461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of emerging and new psychoactive substances in the United Kingdom.
    Beharry S; Gibbons S
    Forensic Sci Int; 2016 Oct; 267():25-34. PubMed ID: 27552699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rise of new psychoactive substance use in Australia.
    Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
    Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syphilis in the Americas: a protocol for a systematic review of syphilis prevalence and incidence in four high-risk groups, 1980-2016.
    Kitayama K; Segura ER; Lake JE; Perez-Brumer AG; Oldenburg CE; Myers BA; Pourjavaheri P; Okorie CN; Cabello RL; Clark JL
    Syst Rev; 2017 Oct; 6(1):195. PubMed ID: 29017552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS).
    Deligianni E; Corkery JM; Schifano F; Lione LA
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28485125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited use of novel psychoactive substances in South London nightclubs.
    Wood DM; Hunter L; Measham F; Dargan PI
    QJM; 2012 Oct; 105(10):959-64. PubMed ID: 22718853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An insight into the deep web; why it matters for addiction psychiatry?
    Orsolini L; Papanti D; Corkery J; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interest in eight new psychoactive substances before and after scheduling.
    Ledberg A
    Drug Alcohol Depend; 2015 Jul; 152():73-8. PubMed ID: 25981311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.